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were $17.44, $9.21 and $13.96 ans the cost/(change in
BPRS) were $2.91, $4.13 and $2.41 for clozapine, ris-
peridone and olanzapine respectively indicating olanza-
pine as the most cost-effective. The difference between
the cost/(change in BPRS) for olanzapine and risperidone
was statistically significant (P  0.036, t  2.1234,
df  98) ($1.72[$3.54–$0.10]). CONCLUSION: Re-
sults of our evaluation indicate that olanzapine is the
most cost-effective antipsychotic in our population of se-
vere and persistently mentally ill patients with schizo-
phrenia and schizoaffective disorders. We recommend
that simple cost-effective evaluations be made in every in-
stitution before deciding on the formulary or the pre-
ferred status of any atypical antipsychotic as it depends
upon many variables.
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The Disability In Strategies for Care (DISC) study dem-
onstrated that stratified care (where more disabled pa-
tients commenced treatment with zolmitriptan 2.5mg) re-
sulted in superior clinical outcomes compared with
conventional stepped care (where patients commenced
the same treatment regardless of disability). However
there are no prospective studies of the cost-effectiveness
of stratified care. OBJECTIVE: To assess the cost-effec-
tiveness of stratified care in managing migraine. METH-
ODS: A decision-analytic model was built to represent
primary care treatment of migraineurs under stepped and
stratified care, according to the treatment regimens in the
DISC study. A health service perspective was adopted,
with a one year time horizon. Data inputs were (i) the
frequency and disability of migraine, derived from popu-
lation-based studies. (ii) disability level-specific treatment
response rates for OTC analgesics, aspirin/metoclopra-
mide and zolmitriptan were obtained from an interna-
tional Delphi study; (iii) unit costs of healthcare in the US
(drug costs, primary and secondary care consultation
costs) obtained from health service sources. RESULTS:
The model estimated the cost per successfully treated at-
tack as $80 for stepped care and $45 for stratified care.
The estimated one-year direct healthcare costs were $534
for stepped care and $546 for stratified care. Estimates of
treatment response rates were 40% and 71% for stepped
and stratified care respectively.The incremental cost-
effectiveness for stratified care was $2.12 per additional
successfully treated attack. The cost-effectiveness of strat-
ified care was robust when tested in a wide range of sen-
sitivity analyses. CONCLUSION: Stratified care is a highly
cost-effective method of managing migraine delivering
improved clinical outcomes at minimal additional cost.
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Managed care companies vary substantially in the health-
care management of their membership as well as the fi-
nancial and contractual arrangement with their provider
networks. Therefore, formulary decision-makers could
benefit from customization of pharmacoeconomic deci-
sion models with plan-specific information. OBJEC-
TIVE: The purpose of this analysis was to validate results
of a pharmacoeconomic model for major depression by
customizing clinical and financial datasets specific to five
managed care organizations (MCOs). METHODS: A
pharmacoeconomic model was developed using decision
tree analysis over a six-month time horizon to assess the
acute phase of major depression for inpatients and out-
patients. Success and failure rates for TCAs, SSRIs and
SNRIs were obtained from a recent meta-analysis. Health-
care resources were incorporated into the model to deter-
mine the inpatient and outpatient costs of patient out-
comes. To facilitate site-specific customization of the
model, a software tool was developed enabling revisions
to the base-case practice patterns, resource valuation and
epidemiologic data. The model calculated expected cost
per patient, expected cost per-member-per-month (PMPM),
total annual cost, and 5-year total cost. RESULTS: Over
the five plans, the expected annual cost per outpatient
was the lowest for venlafaxine at $1,364 to $3,177 and
the highest for SSRIs at $1,881 to $4,311. Similarly, the
expected annual cost per inpatient again was the lowest
at $6,477 to $16,305 for venlafaxine and the highest at
$6,963 to $18,171 for the TCAs. CONCLUSIONS: Al-
though results varied across the five customizations of
the model, venlafaxine XR was the lowest cost alterna-
tive for all plans, validating the pharmacoeconomic re-
sults of the original model.
PMH10
A MODEL TO PERFORM ECONOMIC 
EVALUATIONS OF INTERVENTIONS FOR 
ACUTE MUSCULAR LOW BACK PAIN
Neighbors D1, Earnshaw SR1, Bell L1, Bhattacharyya SK2
1Research Triangle Institute, Research Triangle Park, NC, USA; 
2Procter and Gamble Pharmaceuticals, Mason, OH, USA
Acute muscular low back pain (LBP) accounts for over
$30 billion in US annual medical costs, and is a leading
cause of absenteeism. LBP represents 16% of workers’
compensation claims and 33% of worker’s compensation
costs. Successful LBP treatment can yield substantial sav-
ings for the healthcare system and employers. OBJEC-
TIVE: To develop a model to estimate changes in health-
care utilization, absenteeism, and cost resulting from LBP
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treatments. METHODS: The model is based on pub-
lished treatment guidelines for LBP, modified to reflect
usual care. The model focuses on three types of patients,
those who (1) self-treat only, (2) visit their primary care
physician, and (3) visit a physical therapist. To establish
baseline costs, we included published estimates of health-
care resource utilization, including medications, visits to
healthcare professionals, and various procedures and mo-
dalities. We also included published and calculated esti-
mates of time lost from work due to LBP and provider
visits. The economic analysis takes three perspectives: pa-
tient, healthcare provider, and employer. RESULTS: At
baseline, the employer bears the largest portion LBP costs
($583 per episode), followed by the managed care orga-
nization ($197), and the patient ($56). In exploratory
analyses of a wearable heat wrap that improves physical
functioning during an LBP episode, and shortens the epi-
sode’s length, all stakeholders saved money regardless of
the intervention cost, and experienced the non-monetary
benefits of successfully treating LBP. The employer achieved
the greatest savings. CONCLUSIONS: LBP is a costly
health problem. When evaluating treatments for LBP, it
is important to measure the intervention’s effects on ab-
senteeism and healthcare resource utilization, as well as
pain and physical functioning.
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Acute muscular low back pain (LBP) accounts for over
$30 billion in US annual medical costs, and is the second
leading cause of absenteeism. It represents 16% of work-
ers’ compensation claims and 33% of workers’ compen-
sation costs. LBP is treated by a variety of healthcare
providers (e.g., primary care physicians, physical thera-
pists, chiropractors, and patients). Each of these provid-
ers has a unique treatment approach, which is under-
standable, because it is unlikely that any one treatment
would be beneficial if applied indiscriminately to all LBP
patients. Thus, it would be difficult to develop universal
LBP treatment guidelines. OBJECTIVE: In an effort to
develop an economic model of LBP treatments, we evalu-
ated whether usual practice deviates substantially from
treatment guidelines. METHODS: We compared treat-
ment guidelines compiled by the Agency for Health Care
Policy and Research, and the American Academy of
Orthopaedic Surgeons and the North American Spine
Society to published LBP practice patterns. We also inter-
viewed nationally recognized LBP researchers and cli-
nicians. RESULTS: We found that the treatment guide-
lines are more conservative than usual care. Most
healthcare resources reported in the literature by LBP suf-
ferers and healthcare providers were not specifically rec-
ommended by the guidelines. In addition, the guidelines
and clinical practice suggest treatment practices that do
not require a physician’s supervision. The reliance on
“self-treatment” indicates that patient education initia-
tives may be more fruitful social investments. CONCLU-
SIONS: A variety of healthcare providers treat LBP,
and their approaches vary substantially. No single pro-
vider’s approach seems directly derived from treatment
guidelines. Because of widespread “self-treatment” of
LBP, patient education could yield significant healthcare
savings.
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BACKGROUND: The availability of atypical antipsy-
chotics varies substantially in the UK. Several drug proto-
cols are available for treatment of people with first epi-
sode schizophrenia. Current evidence doesn’t compare
the relative efficiency of these protocols for first episode
schizophrenia. OBJECTIVES: To compare the relative
costs and quality adjusted life years (QALYs) at three
years of 8 antipsychotic protocols for first episode schizo-
phrenia. METHODS: Data were estimated from system-
atic reviews, UK specific statistics and published literature.
A decision analytic model was used with Monte-Carlo
simulation analysis to estimate the expected costs and
QALYs (95% confidence intervals). RESULTS: The 8
protocols gave 32 combinations of drug sequences. The
mean (95% CI) expected costs and QALYs per person for
1st line therapy were: chlorpromazine, £19,600–£21,100
(£19,400–£21,300) and 2.20–2.35 (2.19–2.35); haloperi-
dol £22,800–£24,300 (£22,600–£24,600) and 2.18–2.27
(2.17–2.27); risperidone, £22,911–£22,961 (£22,700–
£23,200) and 2.35 (2.34–2.36); olanzapine £26,800–
£26,994 (£26,500–£27,300) and 2.28–2.31 (2.28–2.31).
The incremental cost/QALY of risperidone versus chlor-
promazine was £54,755–£663,170. The ranking of ex-
pected costs and QALYs were similar for 2nd, 3rd and 4th
line therapy. The incremental cost/QALY of risperidone
versus chlorpromazine was £14,300–£26,000. The incre-
mental cost/QALY of clozapine versus chlorpromazine
for 3rd and 4th line only was £13,700–£18,000. CON-
CLUSIONS: Chlorpromazine may be more efficient as 1st
line therapy. Risperidone and clozapine may be more ef-
ficient for patients failing 1st and subsequent therapy.
The results are uncertain: (i) the analyses were explor-
atory; (ii) differences in expected costs and QALYs may
not be economically important (iii) the quality of clinical
and utility data was poor; (iv) some side effects were ex-
cluded due to lack of data.
